About: Semuloparin sodium

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH). It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement, as well as for patients undergoing chemotherapy.

Property	Value
dbo:abstract	Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH). It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement, as well as for patients undergoing chemotherapy. Like bemiparin, semuloparin is classified as an ultra-LMWH because of its low molecular mass of 2000–3000 g/mol on average. (Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding. (en)
dbo:casNumber	9041-08-1
dbo:fdaUniiCode	V5T10N50RD
dbo:wikiPageID	33777665 (xsd:integer)
dbo:wikiPageLength	3259 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	994398728 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Antithrombotic dbc:Heparins dbr:Low_molecular_weight_heparin dbr:Clinical_trial dbr:Hip_replacement dbr:International_Nonproprietary_Name dbr:Thrombin dbr:Enoxaparin dbr:Factor_Xa dbr:United_States_Adopted_Name dbr:Molecular_mass dbr:Sanofi-Aventis dbr:Bemiparin dbr:Thromboembolism
dbp:atcPrefix	None (en)
dbp:casNumber	9041-08-01 (xsd:date)
dbp:chemspiderid	none (en)
dbp:legalStatus	Investigational (en)
dbp:molecularWeight	2000 (xsd:integer)
dbp:synonyms	AVE-5026 (en)
dbp:unii	V5T10N50RD (en)
dbp:wikiPageUsesTemplate	dbt:Antithrombotics dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Blood-drug-stub
dcterms:subject	dbc:Heparins
gold:hypernym	dbr:Being
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Agent114778436 yago:Anticoagulant102718259 yago:Carbohydrate114792703 yago:CausalAgent100007347 yago:Chemical114806838 yago:Compound114818238 yago:Drug103247620 yago:Heparin103514974 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Medicine103740161 yago:Molecule114682133 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Polysaccharide114994004 yago:Relation100031921 yago:WikicatHeparins dbo:Drug yago:Substance100019613 yago:Substance100020090 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH). It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement, as well as for patients undergoing chemotherapy. (en)
rdfs:label	Semuloparin sodium (en)
owl:sameAs	freebase:Semuloparin sodium yago-res:Semuloparin sodium wikidata:Semuloparin sodium dbpedia-fa:Semuloparin sodium https://global.dbpedia.org/id/4urRW
prov:wasDerivedFrom	wikipedia-en:Semuloparin_sodium?oldid=994398728&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Semuloparin_sodium
is dbo:wikiPageRedirects of	dbr:Semuloparin
is dbo:wikiPageWikiLink of	dbr:Semuloparin
is foaf:primaryTopic of	wikipedia-en:Semuloparin_sodium